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Introduction
The quest for alternative drugs to the well-known cisplatin
and its derivatives, which are still used in more than 50% of
the treatment regimes for patients suffering from cancer, is
highly needed.
1,2 Despite their tremendous success, these
platinum compounds suffer from two main disadvantages:
they are inefficient against platinum-resistant tumors, and
theyhaveseveresideeffectssuchasnephrotoxicity.Thelatter
drawback is the consequence of the fact that the ultimate
targetofthesedrugsisubiquitous:Itisgenerallyacceptedthat
PtanticancerdrugstargetDNA,whichispresentinallcells.
3,4
Furthermore, as a consequence of its particular chemical
structure, cisplatin in particular offers little possibility for
rational improvements to increase its tumor specificity and
thereby reduce undesired side effects.
In this context, organometallic compounds, which are de-
finedasmetalcomplexescontainingatleastonedirect,covalent
metal-carbonbond, have recently been foundtobepromising
anticancerdrugcandidates.Organometallicshaveagreatstruc-
tural variety (ranging from linear to octahedral and even
beyond), have far more diverse stereochemistry than organic
compounds (for an octahedral complex with six different
ligands,30stereoisomersexist!),andbyrationalliganddesign,
providecontroloverkeykineticproperties(suchashydrolysis
rate of ligands). Furthermore, they are kinetically stable,
usually uncharged, and relatively lipophilic and their metal
atomisinalowoxidationstate.Becauseofthesefundamental
differences compared to “classical coordination metal com-
plexes”,organometallicsofferampleopportunitiesinthedesign
ofnovelclassesofmedicinalcompounds,potentiallywithnew
metal-specific modes of action. Interestingly, all the typical
classesof organometallicssuchasmetallocenes,half-sandwich,
carbene-, CO-, or π-ligands, which have been widely used for
catalysis or biosensing purposes, have now also found applica-
tion in medicinal chemistry (see Figure 1 for an overview of
these typical classes of organometallics).
In this Perspective, we report on the recent advances in the
discovery of organometallics with proven antiproliferative
activity. We are emphasizing those compounds where efforts
havebeenmadetoidentifytheirmoleculartargetandmodeof
action by biochemical or cell biology studies. This Perspective
covers more classes of compounds and in more detail than a
recent tutorial review by Hartinger and Dyson.
5 Furthermore,
whereas recent reviews and book contributions attest to the
rapiddevelopmentofbioorganometallicchemistryingeneral,
6,7
this Perspective focuses on their potential application as anti-
cancer chemotherapeutics. Another very recent review article
categorizesinorganicanticancerdrugcandidatesbytheirmodes
of action.
8 It should be mentioned that a full description of
all currently investigated types of compounds is hardly possible
anymore in a concise review. For example, a particularly prom-
ising class of organometallic anticancer compounds, namely,
radiolabeledorganometallics,hasbeenomittedforspacelimita-
tions. Recent developments of such compounds have been
reviewed in detail by Alberto.
9
Metallocenes
Metallocenesisthenameforcompoundswithtwoπ-bonded
cyclopentadienyl(Cp
a) ligandsonametalatom.Researchinto
this class of compounds started in 1952 with the discovery of
Figure 1. Summary of the typical classes of organometallic com-
pounds used in medicinal chemistry.
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ferrocene (bis-cyclopentadienyl iron, Cp2Fe) and the elucida-
tion of its C5-symmetric structure with two equivalent,
π-bonded Cp rings. Because of their symmetrical structure,
such compounds are also frequently referred to as “sand-
wich complexes”. Today, other metal complexes with cyclic
π-perimeters are also sometimes named metallocenes. Com-
pounds with only one π-perimeter are classified as “half-
sandwich metallocenes”, such as the Ru(arene) com-
plexes discussed below in some of the following sections of this
Perspective. Structurally, the bis-cyclopentadienyl complexes
can be classified into two classes, namely, the “classical” ones
with parallel Cp rings and the “bent” metallocenes, which
have other ligands bonded to the metal in addition to the
Cprings(Scheme1).Thesufficientlyrobustmetallocenesused
for medicinal applications contain metals from the iron and
cobalttriad,withFe,Ru,andCobeingrelevanttothisarticle.
The bent metallocenes typically comprise metals from the
earlier transition metals, most importantly Ti, Zr, V, Nb,
Mo in a medicinal context. Interestingly, all medicinally
important bent metallocenes have a cis-dihalide motif as
depictedinScheme1,whichissimilartothecis-dichloromotif
of the well-established anticancer drug cisplatin. This resem-
blancehasspurredinterestinmetallocenesintheearlydaysof
medicinal inorganic chemistry, particularly through the work
of K€ opf and K€ opf-Maier.
10-12
Historically,however,themedicinalpropertiesofferrocene
were previously investigated because it was the first organo-
metallic compound for which antiproliferative properties
werereported.
13Thisreportsparkedthedevelopmentoforgano-
metallic anticancer compounds.
14,15 Ferrocene by itself is not
a particularly toxic compound. It can be injected, inhaled, or
taken orally without causing major health problems. Like
most xenobiotics, it is degraded in the liver by cytochromes.
Because of its aromatic character, a metabolism related to
benzene had been expected and was indeed found experimen-
tally.Asshowninexperimentswithratsthatwereorallygiven
a single dose of ferrocene in sesame oil, ferrocene is enzymat-
ically hydroxylated in the liver and urinally excreted in the
form of conjugates to sulfate (minor product) and glucuronic
acid as the main products.
16 In vitro, intact liver microsomes,
NADPH, and molecular oxygen were found to be necessary
forthehydroxylationofferrocene. This process wasinhibited
in vitro by CO but significantly stimulated in vivo by pre-
treatment of the rats with phenobarbital. These findings give
conclusive evidence that the hydroxylation of ferrocene is
carried out bycytochrome P450 enzymes, similarly to benzene
and many other hydrocarbons. Although such studies have
hardlybeencarriedoutonotherorganometalliccomplexes,it
isnotunreasonabletoassumethatasimilarfateisexperienced
byseveralof themetal-baseddrugsdiscussed inthisarticle, at
leastbythosewhopossessπ-bonded(quasi-aromatic)ligands.
On the other hand, hydroxyferrocene is rather unstable and
decomposes in aqueous solution, finally releasing solvated
iron atoms. Indeed, ferrocene derivativeshave been proposed
as antianemics, and one such compound, ferrocerone, was
clinically approved in the USSR. To the best of our knowl-
edge,thiscompoundwasthefirstmarketedtransitionorgano-
metal drug. In this context, it is worth mentioning that
another ferrocene-containing compound, which is a close
derivative of chloroquine, has successfully passed clinical
phase II trials as an antimalarial drug candidate (ferroquine,
1, Figure 2).
17,18 This compound is now undergoing field
testing and may reach approval as a new antimalarial drug
inthenearfuture.Ferroquinehasanactivitysimilartochloro-
quine on the malaria parasite P. falciparum but most notably
is similarly active against chloroquine-resistant P. falciparum
strains.Ithasbeendiscussedthatchanges inlipophilicity, but
possibly also some redox activation, could be responsible for
the unexpected activity of this ferrocene antimalarial.
18 Fol-
lowing the success of ferroquine, many other organometallic
antimalarialsweresynthesizedandtestedbutasyetwithlesser
success.
The toxicity of ferrocene was also tested in beagle dogs
that were fed up to300 mg kg
-1 per day for 6 months or even
1gk g
-1 f o ru pt o3m o n t h s .
19 While no acute toxicity or even
deaths were observed, massive Fe overload was diagnosed.
However, all the dogs recovered afterward. The ferrocene-
inducedhepaticFeoverloadcouldbereducedaftertheremoval
of large quantities of Fe by repeated venesection.
19
Ferrocene can undergo a one-electron oxidation, yielding
the ferrocenium cation (see Scheme 1, bottom). This cation is
rather stable and the redox reaction is reversible for most
ferrocene derivatives. Simple ferrocenium salts were the first
ironcompoundsforwhichanantiproliferativeeffectoncertain
types of cancer cells was demonstrated.
13 The mechanism of
actionisstilluncertain.NuclearDNA,cellmembrane,andthe
enzyme topoisomerase II
20,21 were proposed as possible tar-
gets.Moreprecisely,Osellaetal.showedthatferroceniumsalts
may generate hydroxyl radicals in physiological solutions.
22
AnearlierreportsuggeststhattheseradicalsdamagetheDNA
in a Fenton-type reaction.
23 The cytotoxic effect of deca-
methylferrocenium tetrafluoroborate (Cp*2FeBF4,C p *=
pentamethylcyclopentadienyl) was correlated to the produc-
tion of 8-oxoguanine, the initial product of DNA oxidation.
Direct evidence for hydroxyl and superoxide radicals stems
from ESR and spin-trapping experiments. In one of the few
studies of this kind, a synergistic effect between Cp*2FeBF4
Scheme 1. (Top Row) Classical Metallocenes with Parallel Cp
Rings (Left) and Bent Metallocenes (Right) with the Medici-
nally Relevant Metals Indicated and (Bottom Row) Reversible
Oxidation Chemistry of Ferrocene
Figure 2. Ferroquine (1) is presently the most advanced organo-
metallicdrugcandidateandabouttoenterphaseIIIclinicaltrialsas
an antimalarial drug.Perspective Journal of Medicinal Chemistry, 2011, Vol. 54, No. 1 5
and the iron-dependent antitumor drug bleomycin was ob-
served.
24 Finally, the cell membrane may be the cellular target
similar to the peroxidation of membrane lipids which is the
consequence of excess hepatic iron. A more detailed review on
the physiological chemistry of ferrocene and the antiprolifera-
tive properties of ferrocene or ferrocenium alone has recently
been given elsewhere.
25
Neuse et al. used an interesting approach to enhance the
cytotoxicity of ferrocene. They bound ferrocene to polymeric
supports such as poly aspartamide.
26-30 The underlying idea
isthatenhancedwatersolubilitymaybeacrucialfactorforthe
activityofferrocene.Thisassumptionisconfirmedbythefact
that the cytotoxicity of ferricenium salts depends greatly on
the nature of the counterion. Indeed, the poorly soluble
heptamolybdate is inactive while ferricenium salts with good
aqueous solubility such as the picrate and trichloroacetate
displayhighantitumoractivity.
13Itmustbenotedthatsmaller
ferrocenyl polyamines were also tested by Brynes and co-
workers at almost the same time but with limited success.
31
Theworkonpolymer-boundferroceneasanticancerdrugshas
recently been reviewed by Neuse.
32
Numerous ferrocene derivatives have been tested for anti-
proliferativepurposes.
33-38Amongthose,aferrocene-acridine
conjugatewasfoundtobehighlycytotoxic.Theacridinemoiety
served to bring the ferrocene close to DNA by intercalation.
36
Wagner and co-workers investigated the activity of borylated
ferrocenes in boron neutron capture therapy (BNCT)
34 and
found that their compounds exhibit an interesting organ dis-
tribution. One derivative in particular was found to penetrate
the blood-brain barrier (BBB), which is of high importance
for the treatment of brain tumors. Schmalz and co-workers
synthesizedseveralnucleosideanaloguesofferrocene
39(e.g.,2
in Figure 3) with IC50 values in the low micromolar range,
although not as low as the iron tricarbonyl nucleoside ana-
logues from the same group (see also the section Metal
Carbonyl Complexes below).
40,41 No molecular target has
been proposed so far for 2, but the structure makes protein
targets, maybe in RNA/DNA synthesis or repair pathways,
likely candidates.
In more general terms, redox activity is a property that is
not unique to metal compounds but frequently encountered
withthem.Itisthusinterestingtocorrelatetheredoxproperties
ofmetalcompoundswithelectrontransfer,oxidativestress,the
formation of reactive oxygen species, and generally the redox
status of cells.
33,42 While it is difficult to determine the exact
“redox potential” or even “redox status” of a whole cell, the
correlationbetweentheredoxactivityofmetalcomplexesand
their antiproliferative properties has been only tentatively
investigated. However, a mechanism whereby redox activa-
tion induces anticancer activity in ferrocene derivatives has
recently been suggested by Jaouen and co-workers.
42 They
substituted phenyl rings in established drugs and natural
productswithferrocenegroups.
43Mostsignificantly,thiswork
has uncovered a group of derivatives of the anticancer drug
tamoxifen, called ferrocifens by Jaouen’s group.
42,44 Tamox-
ifen(3in Figure4) isthefront-linechemotherapeuticagentfor
patients with hormone-dependent breast cancer. Its active
metabolite is hydroxytamoxifen (4 in Figure 4). In general,
breasttumorscanbedividedintotwogroupsdependingonthe
presence(ER(þ))orabsence(ER(-))oftheestrogenreceptor.
Abouttwo-thirdsofallcasesbelongtotheER(þ)type,render-
ing them susceptible to hormone therapy by selective estro-
gen receptor modulators (SERMs) such as tamoxifen and
giving the patients significantly improved chances for successful
treatment compared to the ER(-) group of patients.
42 The
antiproliferativeactionoftamoxifenarisesfromthecompetitive
binding to ERR subtype, thus repressing estradiol-mediated
DNA transcription in the tumor tissue. Unfortunately, expres-
sion of the ERR may become down-regulated under tamoxifen
treatment, whereby the drug becomes ineffective.
It is believed that the same principle explains the activity of
ferrocifens (5) against ER(þ) cancer cell lines. Some SARs
were derived from a group of ferrocene derivatives of tamox-
ifenasshowninFigure4.Replacementofthephenylgroupby
ferrocene reduces receptor affinity by about 40%. Increasing
the length of the dimethylaminoalkyl chain has an adverse
effect on receptor binding. In addition, it also changes the
bioavailability and determines whether estrogenic or anties-
trogenicactivityisobservedinanimalexperiments.Itappears
that an optimum value is around n = 4. While the Z isomers
bind more strongly to the ERR than the E i s o m e r si ni nv i t r o
tests, there is rapid isomerization under physiological condi-
tions. Finally, ferrocifens were shown to be effective anti-
estrogens in MCF-7 breast cancer cell lines (ER(þ)) and
against estrogen-dependent tumor xenografts in nude mice.
Surprisingly,however,compound5withn=4wasshownto
be active against the ER(-) MDA-MB231 tumor cell line,
which lacks the ERR and is hence not susceptible to treatment
with tamoxifens. This indicates a new and different mode of
action for 5. Interestingly, the ruthenocene analogue of 5 also
acts as an antiestrogen in ER(þ) breast cancer cells but lacks
the antiproliferative effect of ferrocifen against ER(-) cell
lines.
45 Other organometallic fragments in place of the ferro-
cenyl group were also tested but were found to be inactive.
44,46
This suggests a dual mode of action for ferrocifen. In addition
to tamoxifen-like binding to the ERR receptor, the second
pathway must critically depend on the properties of ferrocene.
In an elegant study, redox activation has been proposed as the
second mode of action.
47 T h ea c t i v em e t a b o l i t eh y d r o x y f e r r o -
cifen is readily oxidized, yielding a quinone methide intermedi-
ate. This intermediate is activated for nucleophilic attack by
nucleophiles. Quinone methides of the metal-free 4-hydroxy-
tamoxifenareknowntobestableforhoursunderphysiological
Figure 3. Nucleoside analogue of ferrocene. Figure 4. Tamoxifensandferrocifens.Themostactivederivativeof
5 with n = 4 is referred to as the ferrocifen.6 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 1 Gasser et al.
conditions. Adducts of such tamoxifen metabolites with glu-
tathione and nucleobases are thought to be responsible for its
general toxicity and mutagenic potential. It is now proposed
that related chemistry applies to the activated ferrocifens.
ExtensiveSARstudies
48-53incorrelationwithelectrochemical
properties
52,54-56 support this hypothesis. Moreover, produc-
tion of reactive oxygen species has been demonstrated in cell
l i n e st r e a t e dw i t hf e r r o c i f e na n dd e r i v a t i v e s .
57 In this mode of
action, which is summarized in Scheme 2, the metallocenes
serve as a “redox antenna”. It is particularly noteworthy that
redox activity of the metallocene is the key for additional
biological activity that exceeds that of a purely organic ana-
logue. Once this redox-activation mode of action was estab-
lished, it is clearly not dependent on the tamoxifen-related
substructure. Recently, the same group has presentedwork on
ferrocenyldiphenolsandunconjugatedphenolderivativesthat
also have good antiproliferative activity, presumably via a
related mechanism of activation and formation of similar
intermediates.
58,59
In order to advance the use of ferrocifens toward clinical
studies, several formulation studies were performed using
nanoparticles,
60 lipid nanocapsules,
61,62 and cyclodextrins.
63
Further work from the same group includes, beyond synthe-
sis, at least a preliminary testing of the antiproliferative
activity of ferrocene derivatives of several classes of com-
pounds, i.e., curcuminoids,
64 androgen derivatives,
65 and
anti-androgens derived from the nilutamide lead structure,
66
indolones,
67 and ferrocenophane polyphenols.
68
For the bent metallocene dihalides, SARs were established
for the halides, and substitution of the Cp rings
11,14,15,69 and
model studies of such compounds with amino acids, nucleic
acids, proteins, and blood plasma were performed.
70 Tita-
niumcompoundsweremost active, and titanocene dichloride
has even entered clinical trials.
71 Although very promising
in animal models, the clinical response was not significant
enough to justify continuing trials; i.e., titanocene dichloride
clinicaltrialswererecentlyabandoned.Furthermore,because
of its decomposition and low solubility in water, there were
also problems with the formulation of the drug. Earlier work
investigated DNA interaction, induction of apoptosis, and
topoisomerase inhibition as possible modes of action.
72-74
Despite the resemblance of titanocene dichloride with
cisplatin, there has never been clear evidence of a similar
modeofaction,i.e.,bindingtoDNAandeventuallyapoptosis
of the cancer cell.
4 Instead, binding of the Ti
4þ cation to
transferrin following complete hydrolysis of Cp2TiCl2 was
proposed,
75andevenastimulatoryeffectofaqueousTispecies
on hormone-dependent breast cancer cells was observed.
46
From an inorganic point of view, however, the existence of
simple hydrated Ti
4þ cations is highly unlikely in aqueous
solutionatpH7,asoligomericspeciesandeventuallyinsoluble
titanium dioxide will form. A recent computational study on a
benzyl-substituted titanocene (titanocene Y (6), Figure 5) sug-
gests that the Cp(R)2Ti
2þ dication binds to a DNA phosphate
group, with additional interactions stabilizing the binding to
DNA.
76 Although this result is in accord with chemical intui-
tion,i.e.,thehardTicationbindingtoanionicoxygenatoms,it
is a single point computation assuming DNA as the molecular
target. No protein targets were so far considered for the bent
metallocenes.
The two main problems of the titanocene dihalides, i.e.,
poor aqueous solubility and hydrolytic instability, were both
addressed in recent years by chemical synthesis. To increase
aqueous solubility, amino-substituted bent metallocenes were
successfully prepared.
77 The two Cp rings are covalently linked
together in ansa-titanocenes, and indeed, such compounds
exhibit improved hydrolytic stability.
78,79 Both groups of com-
poundsshowpromisingbiologicalactivity.ThegroupofTacke
has developed a versatile synthetic access to Cp-substituted
Scheme 2. Redox Activation of Ferrocifens as Proposed by Jaouen and Co-Workers
a
aThe ferrocene serves as a “redox antenna”. Following oxidation and proton abstraction a quinone methide is formed, which is readily attacked by
nucleophiles at the positions indicated by arrows.
Figure 5. Titanocene Y (6) and the ansa-bridged derivatives tita-
nocenes X (7) and Z (8).Perspective Journal of Medicinal Chemistry, 2011, Vol. 54, No. 1 7
bent metallocenes viathefulvene route.This approach yields
unbridged (via hydrido lithiation) as well as ansa-bridged
metallocenes (via carbo lithiation).
80 In vitro cytotoxicity
tests were performed for several derivatives. A screen against
36 human tumor cell lines of 14 different tumor types on the
derivatives 6-8 (termed titanocenes Y, X, and Z, Figure 5)
revealed thep-methoxybenzyl substituted titanocene Y (6)a s
the most active derivative. Even more interesting, this com-
poundshowedverygoodactivityagainstrenalcellcancerand
pleura mesothelioma cell lines, for which no effective che-
motherapeutic agents are currently available.
81 Further test-
ing of this compound was performed, including tests against
freshly explanted tumors
82,83 and in vivo tests against xeno-
graftedrenalcancer(Caki-1),
84prostatecancer(PC-3),
85and
breast adenocarcinoma (MCF-7) in mice.
82 Mechanistic
studies particularly, but not exclusively, on titanocene Y
revealed antiangiogenic effects but no myelosuppression,
86
activation of the immune system, and induction of apoptosis
via caspases 3 and 7 but not caspase 8.
87,88 This is a desirable
combinationofpropertiesforanticancerdrugs.Inanobvious
extension of their work and inspired by second-generation
platinum drugs, the Tacke group has recently replaced the
two chloride ligands on titanocene Y with carboxylate
groups to yield equallyactivecompoundswithpossiblyeven
more favorable pharmacokinetics.
89,90
WhileCp-substituted vanadocenes, zirconocenes, andeven
stannocenes were recently evaluated,
91-94 more in-depth re-
search has concentrated on molybdocene derivatives as the
most promising alternative to Cp2TiCl2. Again with relation
to cisplatin, DNA was envisaged as the target, and in early
work, several X-ray structures with the Cp2Mo fragment
coordinated to nucleobases were obtained.
95-97 Also early
on,comparativehydrolysisstudiesofseveralbentmetallocene
dihalides were performed that identified Cp2MoCl2 as one
of the most stable simple metallocenes. Unlike Cp2TiCl2,t h e
Cp rings in the Mo derivative are less prone to hydrolysis.
Furthermore, extensive spectroscopic studies, mainly by
1H
and
31PNMR,werecarried out insolutiontoassess thebind-
ing mode of molybdocene dichloride with DNA.
96,98-100 In
more recent work, Harding and co-workers investigated
cellular uptake and intracellular localization of several bent
metallocenes dihalides by X-ray fluorescence.
101,102 Only low
levels of Ti and V were detected inside cells, and only Mo
seemed to accumulate in significant amounts in the cellular
nuclei (Figure 6). Together, these findings agree well with the
notionthatallmetalloceneshaveadifferentbiologicalprofile.
Organometallic Ruthenium Half-Sandwich Complexes
The idea of using ruthenium-containing organometallics
as anticancer agents was first developed by Tochter et al.
103
before being intensively investigated in the Sadler and Dyson
research groups. It was initially anticipated that the binding
of all ruthenium compounds to DNA was the main reason
fortheiranticancereffect,similartotheplatinumderivatives;
i.e., the coordination of the metal center to DNA causes
structural modifications, which would ultimately lead to the
inductionofapoptosis.Indeed,theabilityofrutheniumcom-
plexes to bind to DNA or model compounds has been amply
demonstrated,
104-114 although it was found that the actual
DNA binding of certain ruthenium compounds was weaker
than or/and different from the one observed for platinum
derivatives.
106,115,116 But recent studies for a series of ruthe-
niumanticancercompoundsrevealedthatDNAisnotalways
theprimarytargetandthatthesespecieswereactuallybinding
more strongly to proteins than to DNA.
117-119 These findings
clearlyindicatedtheoccurrenceofsignificantlydifferentmodes
of action, depending on the type of ruthenium complexes.
However, the exact mechanism by which these metallodrugs
exert their effects has not (yet) been fully understood. None-
theless,inthissection,wewillhighlightrecentdevelopmentson
the elucidation of the mechanism of action of anticancer
ruthenium half-sandwich organometallic compounds, as well
astheexactroleofthemetalcenter.Anonexhaustivecatalogue
of ruthenium organometallic antitumor agents can be found in
recent reviews or book chapters.
5,120-123 We will use structure
comparisonstoexplicitthemechanismdifferences/analogiesof
these compounds.
At a first glance, the structural similarity of the half-
sandwich “piano stool” type organometallics presented in
Figure7mightsuggestananaloguousmechanismofcytotoxic
action. However, to the best of our current knowledge, they
appear to be much different.
Salderetal.establishedthatthemechanismofactionoftheir
compounds [(η
6-arene)Ru(en)(Cl)]
þ (en = ethylenediamine)
(Figure7,left)hasmanyofanalogiestothatofcisplatin.Itfirst
involves hydrolysis of the Ru-Cl bond of the prodrug to
generate an active [(η
6-arene)Ru(en)(H2O)]
2þ species. De-
tailed kinetic studies showed that the Ru-Cl bond hydrolysis
canbestronglyinfluencedbythenatureofthecoligandsaswell
as the nature of the metal ion (see also the section Organome-
tallicOsmiumHalf-SandwichComplexesbelow).
121,122Impor-
tantly, this step is suppressed in the blood because of the high
chloride concentrations enabling [(η
6-arene)Ru(en)(Cl)]
þ to
cross the cell and nuclear membranes. Once inside the cell,
the hydrolysis of the chloro anion takes place because of the
muchlowerchlorideconcentration(∼25timeslower).Itisthen
assumed that the aqua complex [(η
6-arene)Ru(en)(H2O)]
2þ
binds to nuclear DNA with a high affinity for the N7 position
ofguaninebasesasshownbyNMRandX-raycrystallographic
studies and transcription mapping experiments.
111-113 It must
be pointed out that the analogy in the mode of action between
[(η
6-arene)Ru(en)(Cl)]
þ and cisplatin stops at this point. In-
deed, the Ru arene compounds can only form monofunctional
adducts compared to cisplatin which is known to form bifunc-
tional adducts and DNA cross-links. Importantly also, [(η
6-
arene)Ru(en)(Cl)]
þ derivatives were found to be active against
Figure 6. Intracellular distribution of Mo (from Cp2MoCl2), Ti(from
Cp2TiCl2), and K as shown by X-ray fluorescence microscopy. Repro-
ducedfromref102,withkindpermissionofSpringerScienceþBusiness
Media.
Figure 7. (η
6-Arene)ruthenium anticancer complexes.8 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 1 Gasser et al.
cisplatin-resistant cell lines, indicating that the detoxification
mechanismisdifferentfromtheoneofcisplatin.
124However,in
silico calculations undertaken by Deubel et al. to compare the
difference in selectivity of cisplatin to organometallic ruthe-
nium complexes toward biological targets show that organo-
metallic ruthenium anticancer complexes are more similar to
cisplatin than to inorganic Ru(II) complexes.
125
Ru-RAPTA derivatives were originally designed to improve
theaqueoussolubility(pta=1,3,4-triaza-7-phosphatricyclo-
[3.3.1.1]decane, Figure 7). As for Ru(II) arene ethylenediamine
compounds, RAPTA derivatives
126 containing two chloride
ligands were also found to be susceptible to hydrolysis and
it was first anticipated that DNA was a primary target.
127
Dyson et al. recently prepared RAPTA carboxylato deriva-
tives (oxalo-RAPTA-C and carbo-RAPTA-C, Figure 8).
128
This work was evidently inspired by the structures of carbo-
platinandoxaliplatin.InanalogytothePtcompounds,itwas
assumed that the carboxylato ligands would hydrolyze more
slowly and in a more controllable way than the chloride
ligands in the original RAPTA-C compound. These RAPTA
derivativeshaveaninvitroactivity similartothatofRAPTA-C.
All evidence taken together, RAPTA compounds seem to
operate by a different mode of action compared to cisplatin,
Ru(II) arene ethylenediamine compounds, and most of the
knownanticancercompoundsingeneral.Invitrocytotoxicity
studies showed that these compounds were much less cyto-
toxicthancisplatin.Indeed,manyoftheRAPTAcompounds
could not even be classified as cytotoxic and were also non-
toxic to healthy cells. The extent of this nontoxicity was
proven in an in vivo study when healthy mice were treated
atquitehighdoses withRAPTA compounds withouttrigger-
ing toxic side effects.
129 But the most striking result observed
wasthatbothRAPTA-C andRAPTA-Tinhibitedlungmetas-
tasisinCBAmicebearingtheMCamammarycarcinoma(the
number and weight of the metastases were reduced) while
having only mild effects on the primary tumor.
2 The only
other metallo drug candidate displaying this outstanding be-
havior is imidazolium trans-[tetrachloro(dimethylsulfoxide)-
(1H-imidazole)ruthenate(III) (NAMI-A).
2,118 This discovery
is of high practical interest, as the removal of the primary
tumorbysurgeryisfrequentlyanefficientprocedurewhilethe
treatment options for metastases are quite limited.
2
Nonetheless, these very exciting findings engendered natu-
rallyanewandobviousquestion:IfDNAisnotthetargetfor
these RAPTA derivatives, then what is the target? The final
answer has not yet been determined, but at this stage of the
research, enzyme bindingis the most probableexplanation.It
was shown by mass spectrometry that RAPTA compounds
form adducts with proteins
130 and that the reactivity of
RAPTA-Candcisplatininthepresenceofproteinswasmuch
different.
131 To get more insight, Messori et al. studied the
inhibition activity of a series of RAPTA compounds to two
proteins, i.e., cathepsin B (Cat B) and thioredoxin reductase
(TrxR), which are possible targets for anticancer metallo-
drugs.
132 They found that all tested Ru compounds were
inhibitors of Cat B while none of them, with the exception
of RAPTA-C, was inhibiting TrxR. Computer docking ex-
perimentsvalidatedthisfinding.Assumingthatoneofthetwo
chloride ligands of the RAPTA derivatives was first replaced
by a water molecule, it was then found that the Ru(II) center
coordinates to the active site cysteine residue. Furthermore,
other atoms of RAPTA (chloride, nitrogen of pta, etc.) bind
otheraminoacidsofCatB,therebystabilizingthemetallodrug-
enzyme complex.
132 Interestingly, a good correlation was
observed between the inhibiting potency of the RAPTA
derivatives and the calculated stability of the corresponding
Cat B/RAPTA adducts.
132
Other proteins have been proposed as the target for Ru
organometallics.P-Glycoprotein(Pgp)isaplasmamembrane
protein that is responsible for drug efflux from cells and is
involvedinmultidrugresistance(MDR).
120InhibitorsofPgp,
namely,phenoxazineandanthracenederivatives,weresynthet-
ically modified and coordinated to Ru organometallics.
133
The aim was to obtain a synergistic effect by combining the
selectivityofrutheniumcomplexestowardcancercellsandthe
ability of the phenoxazine and anthracene derivatives for Pgp
inhibition.Thesenewlyformedcomplexeswerefoundtobe,in
general,morecytotoxicandinhibitedtoalesserextentthePgp
protein than the original Pgp inhibitor derivatives used as
ligands. Interestingly, for one of these ruthenium derivatives
(13, Figure 9), it was shown that the ruthenium coordination
to the Pgp inhibitor derivative induced an even stronger pro-
tein inhibition. Furthermore, because of the presence of the
fluorescent anthracene group, it was observed that 13 was
accumulating in cell nuclei, suggesting a DNA synthesis inhi-
bition as the mechanism of cytotoxic action. Nonetheless,
because ofthe strong increase in cytotoxicity uponruthenium
coordination, Dyson et al. believe that their organometallic
compound not only inhibits the enzyme but also induces cell
death via a second mechanism, implying a bifunctionality of
this compound.
133
In a similar line of thought, namely, a dual cytotoxic mode
of action, ethacrynic acid (EA) was coupled to two RAPTA
derivatives(15and16,Figure9)
134aswellastootherRuarene
organometallics.
135 EA is an effective glutathione transferase
(GST) inhibitor, which has been investigated as a potential
anticancer drug. EA is known to bind competitively to the
hydrophobic cosubstrate (H-site) of GST, while the RAPTA
compounds are recognized to react with soft nucleophilic
centers such as thiol groups (see above).
134 15 and 16 com-
pounds were therefore thought to be able to bind not only to
the enzyme at the H-site but also to interact with the reactive
cysteineresiduesofGSTP1-1(thisGSTproteinpossessestwo
solvent-accessible cysteine residues that affect catalytic activ-
ity when modified). As assumed, these two new compounds
were found to bind the catalytic H-site in a similar fashion as
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EA.Furthermore,theinhibitionconstantsKiofthecomplexes
on GST P1-1 were 3 or 4 times lower than EA. The authors
therefore concluded that the ruthenium centers were also
involved in the inhibition of GST P1-1. Interestingly, it was
demonstrated by X-ray crystallography and by ESI-MS that
16 decomposed, over a period of time, into a ruthenium
derivative and EA. It is anticipated that the cleavage occurs,
by virtue of a possible allosteric effect or simply over time,
whentheEAmoietyof16isboundtotheH-site.Importantly,
this (selective?) release of the ruthenium moiety should en-
hance the toxic effect of the compound on cancer cells, which
hadalready been sensitizedbytheEAmoietythatinactivated
GST.
134 This feature could be used to specifically deliver a
cytotoxic payload for targeted chemotherapy.
134
Still in a metal-drug synergism context, the group of
S  anchez-Delgado coupled different Ru arene complexes to
chloroquine (CQ), which is known to be an effective antima-
larial compound as well as having anticancer properties (see
thesectionMetallocenesabove).
136Contrarytotheferroquine
mentioned above,
17,137 in which the ferrocenyl moiety is non-
toxic (or at least commonly assumed to be), these compounds
are made of two toxic moieties. The compounds had a con-
sistentlyhigherpotencyagainstCQ-resistantparasitesthanthe
standard drug chloroquine diphosphate (CQDP). In addition,
two of their compounds (17 and 18, Figure 10) inhibit the
growth of two HCT-116 colon cancer cell lines with IC50 values
between20and35μM.Theyalsoobservedthatliposarcomacell
lines were especially sensitive to 17 with an IC50 value of 8 μM.
Thisisofclinicalinterest,asthistypeoftumordoesnotrespond
to currently employed chemotherapies.
136
Otherproteinshavebeenshowntobethetargetofcytotoxic
ruthenium organometallics. For example, Sheldrick et al. have
used an automated multidimensional protein identification
technology (MudPIT), which combined biphasic liquid chro-
matographywithelectrosprayionizationtandemmassspectrom-
etry (MS/MS) to analyze tryptic peptides from Escherichia
coli cells, which were first treated with [(η
6-p-cymene)RuCl2-
(DMSO)] (14, Figure 9).
138 They showed that five proteins,
namely, the cold-shock protein CspC, the three stress-response
proteins ppiD, osmY, and SucC, and the DNA damage-
inducible helicase dinG were the target of their Ru arene com-
pounds.
138 Using electrophoretic mobility shift assays, Brabec,
Sadler and co-workers also examined the binding properties of
the mismatch repair (MMR) protein MutS in Escherichia coli
with various DNA duplexes (homoduplexes or mismatched
duplexes) containingasinglecentrallylocatedadductofRu(II)
arene compounds.
139 They showed that the presence of the
Ru(II) arene adducts decreased the affinity of MutS for
ruthenatedDNAduplexes,whicheitherhadaregularsequence
or contained a mismatch, and that intercalation of the arene
contributed considerably to this inhibitory effect.
139
Interestingly, it was recently demonstrated that iodo-
containing Ru(II) arene organometallic derivatives 19 and 20
(Figure11) werehighlycytotoxictohumanovarianA2780and
human lung A549 cancer cells. Although these complexes are
remarkably inert toward ligand substitution. No hydrolysis
was observedbyNMR andESI-MS.
140Fluorescence-trapping
experiments in A549 cells suggested that this potency arose
fromanincreaseinreactiveoxygenspecies(ROS).Surprisingly,
these Ru complexes act as catalysts for the oxidation of the
tripeptide glutathione (GSH), which is a strong reducing agent
presentinmillimolarconcentrationsincells.Indeed,millimolar
amounts of GSH were oxidized to glutathione disulfide in the
presence of micromolar ruthenium concentrations! The same
group showed that the anticancer complex [η
6-bip)Ru(en)Cl]
þ
21(bip=biphenyl) (Figure11) readilyreactswithGSH,atpH
7, in a typical cytoplasmic concentration of chloride and at Ru
concentrations relevant to cytotoxicity to give a thiolato com-
plex[η
6-bip)Ru(en)(GS-S)] asthemajorproduct.
113Unexpect-
edly, this complex is very sensitive to air and is oxidized to the
sulfenato complex [η
6-bip)Ru(en)(GS(O)-S)]. However, under
physiologically relevant conditions, competitive reaction of
complex 21 with GSH and guanosine 30,50-cyclic monophos-
phate(cGMP) gaverisetoacGMPrutheniumadduct,account-
ing for 62% of total Ru, even in the presence of a 250-fold
molar excess of GSH.
113 This suggests that oxidation of
Figure 10. Ru arene chloroquinone antimalarial and antitumor
agents.
136
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coordinatedglutathioneinthethiolatocomplextothesulfenate
providesafacileroutefordisplacementofS-boundglutathione
by the guanine N7 atom, a route for RNA and DNA ruthena-
tion even in the presence of a large excess of GSH.
113
Itmustbepointedoutthat Sadleretal.recentlyunambigu-
ously identified diruthenium and tetraruthenium clusters
when complex 21 was reacted with GSH, using nanoscale
liquidchromatographyFouriertransformioncyclotronmass
spectrometrycombinedwith
18O-labeling.
141Thesamegroup
also recently observed the binding of Ru arene compounds
with human serum albumin by means of mass spectrometry
combined withtrypsindigestion, specific side chain modifica-
tions, and computational modeling.
142 Finally, a loss of cyto-
toxic activity of Ru arene organometallics upon oxidation of
their amine ligand such as o-phenylenediamine (o-pda) to the
corresponding imine ligand o-benzoquinonediimine (o-bqdi)
(Figure 12) was observed.
143 For example, the IC50 values
against A2780 ovarian cancer cells of 22 is 11 μMw h i l e
compound 23 displays a value above 100 μM. Interestingly,
the o-bqdi complexes can be reduced by GSH but readily
undergo reoxidation in air.
Dyson et al. recently described the preparation of a series
of RAPTA-type complexes with fluoro-substituted η
6-arene
ligands.
144 Electron-withdrawing fluoro or CF3 units were
added to the arene to modulate the pKa values of the com-
plexes. The activity of these organometallics was found to be
strongly influenced by the presence of the substituents. IC50
values of the fluoro compounds were in general much lower
than those of the nonfluorinated analogues.
Organometallic Osmium Half-Sandwich Complexes
Probablybecauseofitsreputationofbeinghighlytoxic(see
OsO4) and relatively inert toward substitution, osmium organ-
ometallics have been neglected as therapeutic agents in com-
parison to its lighter congener ruthenium.
121,145 Recently
however, several research groups
146-154 investigated the anti-
cancer activity of osmium(II) arene half-sandwich complexes.
Their results indicate that Os(II) organometallics might be
promising candidates as antitumor drugs.
The kinetic and thermodynamic properties found for the
first Os complexes were unsatisfactory despite the fact that
they were isostructural to the active Ru complexes.
121
Concomitantly,thebiologicalactivitywaslow.SARswerethen
established and then used to improve their activity. The ligand
exchange rate (chloride against water, see discussion above
in the section Organometallic Ruthenium Half-Sandwich
Complexes) was too slow (40-100 times slower than the Ru
analogues, depending on the pH value). The water bound to
th eo s m i u mi si n d e e dm o r ea c i d i cb y1 -2p Kaunits than when
bound to analogous ruthenium complexes. In order to restore
activity, a new series of Os complexes were prepared in which
the neutral N,N-chelate ethylenediamine was replaced by O,O
and N,O anionic chelating ligands with a stronger trans effect.
Following this thought, picolinate was identified as an ideal
ligand candidate and the respective complexes [(η
6-arene)Os-
(pico)Cl](24,Figure13)hadfasterhydrolysisratesandpotent
anticancer activity comparable to that of carboplatin.
148
Furthermore, their mechanism of action is thought to be
similar to that of their Ru organometallics, nuclear DNA
being the biological target asshown bystudies demonstrating
the binding of such complexes to DNA.
150
Arion,Keppler,andco-workersinvestigatedthebindingof
ruthenium and osmium to paullone derivatives, which are
known to be potent inhibitors of cyclin-dependent kinases
(CDKs) (25,F i g u r e1 3 ) .
152 This “metalation” was thought to
increase the solubility and bioavailability of the paullone
ligands. They showed that complexes such as 25 had respect-
able antiproliferative activity in submicromolar to very low
micromolar concentrations in three cell lines, with no signifi-
cant differences between the Os and Ru complexes. No CDK
inhibitionwaspublishedsofaronthosecompounds,andtheir
binding to 50-GMP was found to be significantly different
depending on the complexes. This indicates that they exert
their anticancer activity either by binding to crucial proteins
or by noncovalent DNA interactions.
152
Dyson et al. have also evaluated the activity of Os(II) and
Rh(III) analogues of RAPTA-C (26, 27, Figure 13).
153,154
Depending on the cell lines, significantly different IC50 values
weredeterminedfor26,27,andRAPTA-C,with27beingmore
cytotoxic than the two other compounds and 26 exhibiting
essentially similar cytotoxicity as RAPTA-C.
154 Furthermore,
using a combined experimental and theoretical approach, it
wasreportedthatthebinding of RAPTA-Cand26 toa 14-mer
oligonucleotide was nonspecific contrary to cisplatin, indicat-
ing a different mechanism of action and/or a different biolog-
ical target.
153
Telomerase is a ribonucleoprotein with DNA polymerase
activitythatmaintainsthelengthoftelomericDNAbyadding
hexamericunitstothe30 singlestrandterminus.Itisthereforea
crucial enzyme for cancer progression. Rosenberg, Osella, and
co-workers investigated telomerase inhibition by a series of
water-soluble cyclometalated benzoheterocycle triosmium
clusters (28-31, Figure 14).
155 Their motivation was that
quinoline derivatives had shown interesting biological prop-
erties, especially in inhibiting enzymes.
156 Among all com-
pounds, only the negatively charged clusters (by virtue of the
Figure 11. Structures of catalytically active organometallic anticancer complexes.
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sulfonated phosphines) exhibited good activity as telomerase
inhibitors when tested on semipurified enzymes in a cell-free
assay. However, they were ineffective in vitro on Taq, a dif-
ferent DNA polymerase. Furthermore, none of the osmium
clusters decreased the telomerase activity in the MCF-7 breast
cancer cell line, as observed by the telomeric repeat amplifica-
tion protocol (TRAP assay). This may well be due to the low
aptitude of these organometallics to cross the cell membrane.
However, all compounds were acutely cytotoxic, probably
because of their accumulation on cell membranes, as shown
for compound 29a by inductively coupled plasma mass spec-
trometry (ICP-MS). It was hypothesized that 29a interfered
with the normal trafficking and functions of the membrane.
Gobetto, Rosenberg, and co-workers also investigated the
interaction of other positively and negatively charged trio-
smiumcarbonylclusterswithalbumin,usingthetransverseand
longitudinal relaxation times of the hydride resonances as
1H
NMRprobesofbinding to the protein.
157Evidenceofbinding
was observed for both the positively and negatively charged
clusters. However, they exhibit distinctly different rotational
correlation times.
157 It was anticipated that the negatively
charged clusters bind more tightly than their positive ana-
logues, as albumin is rich in positively charged amino acids.
157
The same researchers also established guanines as the binding
sitesforanotherpositivelychargedwater-solublebenzohetero-
cycle triosmium cluster to single- and double-stranded DNA
by using a range of different biochemical methods.
158
It is worth mentioning that Os3(CO)9 type clusters and
dicobaltcarbonylfragmentswerealsoreactedwithderivatives
oftamoxifen,awidelyuseddruginthetreatmentofhormone-
dependent breast cancer (see also the section Metallocenes
above).
159 The organometallic moiety was found to increase
the lipophilicity and reducedthe affinity, via sterichindrance,
for the estrogen receptor, but no cytotoxicity studies were
carried out on the compounds.
Organometallic Iridium and Rhodium Complexes
In contrast to their Ru(II) congeners, the isoelectronic
Rh(III) and Ir(III) half-sandwich compounds have attracted
much less attention as potential anticancer agents.
154,160-162
But interestingly, among the few examples reported in the
literature, different biomolecules were reported as (potential)
targets. Nevertheless, even though it was shown that these
compounds were indeed targeting the desired biomolecules,
their exact mode of cytotoxic action is still unknown. Hence,
Sheldrick et al. showed that Ir(III) and Rh(III) complexes
such as 32 (Figure 15) bind DNA through intercalation of
Figure 13. Os(II) arene anticancer compounds.
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their polypyridyl ligands.
160,161 Polypyridyl-containing half-
sandwich complexes with Ru(II) and Rh(III) central atoms
and hexamethylbenzene or pentamethylcyclopentadienyl li-
gands showed stable intercalative binding with DNA and
exhibited excellent cytotoxic activities.
114,161 Cellular uptake
studies by atomic absorption spectroscopy (AAS) revealed
that the antiproliferative effects of the complexes were mainly
correlated to the size of the polypyridyl ligands, thereby high-
lightingthespecialroleofligandlipophilicityonthebioactivity
of this class of organometallic antitumor drug candidates.
Whereas an interaction with the DNA might significantly
contribute to the cytotoxic activity of the agents, the presence
of additional cellular targets or alternative modes of action is
very likely to contribute to this activity and is therefore the
subject of ongoing research projects.
Another example of anticancer Ir(III) compounds has
been reported by Lo and co-workers. In order to design
new biological probes for bovine serum albumin (BSA), Lo
et al. prepared a series of luminescent Ir(III) complexes (33,
Figure15) containinganindolederivative(indoleisknownto
bindtoBSA) whichwerefound tobehighlycytotoxictoward
HeLa cells.
162 It is also interesting that other cationic Ir(III)
complexes have been recently reported for phosphorescence
staining in the cytoplasm of living cells and were shown to be
noncytotoxic.
163
Interestingly, the heterobiorganometallic ferrocene-con-
taining Rh(I) derivative 34 (Figure 15) had a similar cytotoxi-
city in prostate cancer cell lines to cisplatin but a significantly
different pathway for activationof cell death.
164 While cisplat-
in predominantly induces apoptosis, 34 induces late necrosis
and abnormal nuclear morphology.
164 This latter finding is of
interest because apoptosis-resistant cells might be better killed
withdrugsinducingthenecroticpathway.
164Furthermore,the
same complex 34 and other related Rh(I) and Ir(I) analogues
(35 and 36, Figure 15) were also found to be cytotoxic toward
Chinese hamster ovary (CHO) cells with the Rh(I) complexes
having IC50 values close to that of cisplatin, while the Ir(I)
c o m p l e xh a das l i g h t l yh i g h e rI C 50 value.
165 Thesecompounds
were also tested for their capacity to sensitize hypoxic CHO
cells against irradiation. Indeed, tumors are notoriously hyp-
oxic and radioresistant. Both factors limit the success of
radiotherapy. Modulation of the radiosensitivity by drugs
such as cisplatin is in routine clinical application.
165 Indeed,
the Rh(I) complex 34 proved to be an excellent radiosensitizer
with properties similar to those of cisplatin.
165
Rhenium Organometallics
Re organometallics are another very new class of promis-
ing antiproliferative compounds. Until recently, only few
examples of cytotoxic Re complexes were described in
the literature.
166-168 However, over the past years, several
compounds with interesting cytotoxicity were reported and
their possible mode of action was explored.
169-174 A non-
exhaustive list of toxic Re compounds is presented in Figure
16. It is still premature to draw any definite conclusions on a
molecular basis for the activity of the Re organometallics
presented in this figure. However, a few targets are now
envisaged. Hor and co-workers assumed that complexes such
as 40 and 41 (Figure 16) were likely to bind to DNA bases or
side chains of amino acid residues in peptides and proteins
after displacement of the labile ligands.
166,167 Other related
Re compounds such as [Re2(μ-OH)3(CO)6]
-, [Re2(μ-OH)-
(μ-OPh)2(CO)6]
-, [Re2(μ-OMe)2(μ-dppf)2(CO)6]
-, and [Re2-
(μ-OPh)2(μ-dppf)2(CO)6]
- (dppf = 1,10-bis(diphenylphosphino)-
ferrocene) have been shown to interfere with nucleic acid
metabolismatmultipleenzymesitesinL1210lymphoidleuke-
mia cells, causing DNA strand scission after 60 min of incu-
bation.
168 Ma et al. observed by spectroscopic titrations
and viscosity experiments that complex 39 (Figure 16) had a
modest DNA binding constant and was interacting with
DNA via groove binding.
169 Modeling studies suggested that
the minor groove was the favored binding site.
169 Lo et al.
prepared and carefully characterized a series of luminescent
Re complexes such as 37, 38,a n d44, which were generally
highly cytotoxic.
172-174 However, the exact target or mecha-
nism of action of these compounds is unknown at this stage
of the research. Recently, Doyle, Zubieta, and co-workers
prepared two new fluorescent Re tricarbonyl bioconjugates,
namely, a folate (43)
170 and a vitamin B12 (45)
171 conjugate
(Figure 15). 43 was screened against a doxorubicin- and
cisplatin-resistant human ovarian cancer cell line (A2780/AD)
which overexpresses thefolatereceptor (FR). Asexpected,43
was internalized by a folate receptor-mediated endocytotic
pathway in this cell line. In contrast, no internalization of 43
was observed with a FR-negative Chinese hamster ovary
(CHO) cell line. 43 was more cytotoxic than cisplatin toward
the FR-positive cell line. The toxicity of 43 was attributed to
intercalation into DNA. The structure of the DNA complex
with43isconsistentwiththecriteriaforminor-groovebinding
with the quinoline rings preferring the A3T sites of the helix
and with the positive charge contributed by the metal ion.
170
Interestingly, no inhibition of topoisomerase I activity was
observed with the Re complex of 43.
170
The fluorescent Re bioconjugate 45 (Figure 16) was pre-
pared to target the cubilin receptor through the vitamin B12
uptake pathway.
171 Vitamin B12 is important for rapidly
growing cancer cells and is therefore an interesting carrier for
drug delivery assuming that receptors involved in its uptake
can be targeted. In vitro antiproliferative cell assays against
cubilin-expressing placental choriocarcinoma BeWo and
CHO cell lines were undertaken, and 45 was found to be only
moderately cytotoxict o w a r dB e W oc e l l s( I C 50 =3 7 6μM).
T h ep a r e n tR ec o m p o u n d42 was found to be 10 times more
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cytotoxic than 45 (Figure 16),
171 probably because of a more
rapid cellular uptake of 45 due to passive diffusion. Aggrega-
tion of 45 in the cytosol and in the nucleus was observed. The
positively charged rhenium chelate component is envisaged to
interact with the negatively charged DNA backbone, thus
playing a role in the observed cytotoxicity.
171
Ruthenium, Osmium, Iridium, and Platinum Organometallics
as Scaffolds for Protein Kinase Inhibitors
245
With the exception of DNA-intercalating compounds,
the metal center is likely to play a direct role in the anti-
canceractivityofmostcompoundsdiscussedsofarbybinding
DNA and/or proteins. In contrast, Meggers et al. have used
metal complexes as structurally inert scaffolds for enzyme
inhibitors.
175-177 Their initial idea was that the spatial orga-
nizationofthesubstituentsaroundthemetalcenterofametal
complex is much more versatile and therefore increases
substantially the opportunity to build complicated three-
dimensional enzyme inhibitor structures. Importantly, the
metal is not playing any direct role in the inhibition; it “only”
allows the spatial organization of the substituents around the
metal center. Their chosen targets were protein kinases that
areknowntoregulatemanyaspectsofcellularphysiologyand
pathophysiology.
178 The mutations and deregulation of pro-
tein kinases play a causal role in many human diseases,
makingthemanimportanttherapeutictarget.
177Eightkinase
inhibitors are already clinically approved, while several more
are in the pipeline. Numerous indolocarbazole alkaloid deri-
vatives such asstaurosporinewerefound tobe potent protein
kinaseinhibitorsthroughhydrogen-bindingtotheATPbind-
ing site (Figure 17).
176 However, a central drawback in the
design of these kinase inhibitors is the fact that kinases form
one of the largest families of enzymes with highly conserved
ATP binding sites, thus rendering the design of selective
inhibitors very challenging.
177 To overcome this limitation,
Meggers et al. synthesized a significant number of metal-
containing enzyme inhibitors, the majority of them being Ru(II)
complexes and some Pt and Os derivatives (see Figure 18
for a few examples of Ru(II) complexes). They successfully
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designed nanomolar and even picomolar ATP-competitive
ruthenium-basedinhibitors.Thisconcept hasbeenconfirmed
by, so far, six different cocrystal structures of Ru complexes
with protein kinases.
179,180 As expected, the metal ion played
solely a structural role (Figure 19). However, the organic
ligands can be optimized to occupy the available space in the
active site, as well as providing additional hydrogen bonding
interactions, thus making the individual inhibitors highly
specific. Moreover, physiological functions as a consequence
of kinase inhibition were demonstrated within mammalian
cells, Xenopus embryos, and zebrafish embryos.
Rucomplexesseemlikeidealcandidatesforthispurpose,as
they are chemically stable in air, water, and buffer containing
millimolar concentrations of thiols, as well as being confi-
gurationally stable against ligand exchange or scrambling
around the metal center.
177 Other advantages are the well
established synthetic chemistry of Ru complexes, a moderate
priceofthestartingmaterial(RuCl3),andlowtoxicityofsuch
compounds.
177 Recently this concept of drug design was
extendedtoinertiridium(III)speciesfeaturingahighlypotent
and selective inhibitor of the kinase Flt4, which also demon-
strated strong antiangiogenic effects in zebrafish embryos.
183
Metal NHC Complexes
Transition metal carbene complexes are organometallic
compounds featuring a divalent organic ligand, which is co-
ordinated to the metal center (see Figure 1). N-Heterocyclic
carbenes (NHCs) are generally derived from the so-called
persistent carbenes, which are stable compounds of divalent
carbon. As they are strongly stabilized by π-donating substit-
uents, NHCs are good σ-donors. However, π-bonding with
the metal is weak. Metal NHC complexes are well-known for
theircatalyticproperties.Additionally,theirhighstabilityand
ease ofderivatization make them suitablecandidates for drug
development.
184,185
Initial reports on the biological application of NHC com-
plexes dealt with the discovery of new antimicrobal com-
pounds and have also stimulated the evaluation of these
compounds as antiproliferative agents.
186-191 For example,
the cationic gold imidazolidine derivative 49 displayed excel-
lent activity against the growth of several species including
Pseudomonas aeruginosa and Staphylococcus aureus (Figure
20).
187 Most efforts in the development of carbenes as anti-
biotics have been focusing on NHC silver complexes. Silver
complexes have a long tradition as anti-infectives; however,
their mode of action is not yet completely understood. Inter-
actions with the bacterial cell walls and the related biochem-
istry seem to be of relevance.
189 The pyridine-linked silver
carbene complexes 50 and 51 exhibited higher bacteriostatic
effects than silver nitrate.
188 Promising antibacterial activities
were also obtained with complex 52, which showed substan-
tially higher stability in aqueous media than structurally
related silver NHC complexes without Cl substituents.
192
Interestingly, 52 and structurally related species were also
active against the growth of certain cultured tumor cells and
preliminary studies on 52 using an ovarian cancer xenograft
model also indicated in vivo antitumor activity.
193 Indeed, as
outlined in more detail below, metal NHC complexes are
promising candidates for the development of bioorganome-
tallic anticancer therapeutics. In most cases, structures de-
scribed as antiproliferative are closely related to the above-
mentionedantibacterialagents,therebyhighlightingthebroad
applicability of the class of transition metal species.
In 2004, Barnard et al. reported the induction of mitochon-
drial permeability transition in isolated rat liver mitochondria
bydinuclearAu(I)carbenecomplexes.
194Thisresultisofspecial
interest,asgoldcomplexeshavebeendiscussedasagentswith
an antimitochondrial mode of action since early studies on
Au(I) phosphine drugs. Moreover, evidence that the impair-
ment of mitochondrial functions is a major route of gold
Figure 17. BindingofATP(left),staurosporine(middle),andruthemiumcomplexes(right)totheATP-bindingsiteofcyclindependentkinase
2 (CDK2). The green area indicates a patch of high hydrophobicity. Adapted from refs 176 and 181.
Figure 18. ExamplesofRu(II)organometallicsaskinaseinhibitors
with their IC50 values. IC50 values were measured at 100 μM ATP if
not indicated otherwise.
Figure 19. Schematic view of how the metal complex mimics the
overall shape of staurosporine. Adapted from refs 177 and 182.Perspective Journal of Medicinal Chemistry, 2011, Vol. 54, No. 1 15
metallodrug activity keeps steadily increasing.
195,196 This
antimitochondrial mode of action of many gold species is
commonlyrelatedtotheinhibitionofthemitochondrialform
of thioredoxin reductase (TrxR), a protein closely related to
glutathione reductase. TrxR is involved in various physio-
logical processes (including proliferation) and is overexpressed
inseveralcanceroustissues.TheactivesiteofmammalianTrxR
contains a selenocysteine residue, which is considered to be the
target of gold metallodrugs.
196,197
Antimitochondrial effects (induction of Ca
2þ-sensitive mi-
tochondrial swelling) were also noted for a series of mono-
nuclear, linear, cationic [Au(NHC)2]
þ complexes.
198 The on-
setofmitochondrialswellingwasmostrapidlyinducedbythe
complexeswiththehighestlipophilicity,whichwasinlinewith
previous studies on gold(I) species demonstrating that the
bioactivity can be influenced by fine-tuning of the lipophili-
city. A complex (53) withintermediate lipophilicity was selec-
ted for further studies confirming the significant antimito-
chondrial properties. It was found that 53 induced apoptosis
via caspase 9 and caspase 3 activation. Furthermore, 53
inhibited TrxR activity in MDA-MB-231 cells and accumu-
lated in mitochondria.
199,200 Structurally related Au(I) NHC
complexes containing one NHC ligand and one chloro ligand
(see 54 in Figure 20 for a relevant example) exhibited potent
inhibitory activities against protein tyrosine phosphatases,
a family of enzymes involved in various physiological pro-
cesses.
201 In analogy to the interaction of various gold com-
plexes with cysteine and selenocysteine residues of TrxR or
glutathionereductase(GR),
196,197acysteineresiduewithinthe
catalyticsiteofproteintyrosinephosphatasesismostprobably
the main molecular target for this kind of NHC complexes.
Recently, Lemke et al. reported a series of gold NHC com-
plexes with promising antiproliferative poteny including
Au(III) species as well as derivatives containing cysteine thio-
late ligands.
202 Both the Au(III) and cysteine-modified NHC
derivatives showed similar biological activities compared
to related Au(I)NHC complexes without cysteine-derived
ligands.Thisthereforestronglysuggeststhatthedevelopment
of structurally diverse bioactive gold NHC species is possible
and thatactivityaswellaspharmacokinetic propertiescan be
optimized by appropriate choice of the oxidation state of the
metal and more sophisticated ligands. In this context, NHC
complexes can be functionalized with peptide ligands, which
opensthepossibilityofdevelopingmetalNHCderivativesfor
targeted drug delivery.
203
Besides the mentioned gold and silver derivatives, NHC
complexes with palladium,
204 nickel,
205 copper,
206 or plati-
num
207 have also been recently reported to exhibit antiproli-
ferative properties. Thus, the copper NHC complex 55 was
more cytotoxic than cisplatin. Complex 55 induced apoptosis
and, unlike cisplatin, arrested the cell cycle progression in
the G1 phase. Concerning a plausible mode of action for this
compound, its nuclease-like activity and O2-activating prop-
erties, which led to DNA strand breaks, appear to be of high
relevance.
185,206 Trans-configured square planar platinum(II)
species (see 56 in Figure 20 for a relevant example) also
demonstrated promising activity in a cisplatin-resistant cell
line.
207
Overall, metal NHC complexes display promising pharma-
cologicalpropertiesasnovelantibacterialandantitumordrugs.
Regarding their mode of action, the choice of the coordinated
metal most probably determines the respective main biological
target, e.g., thioredoxin reductase or other enzymes containing
(seleno)cysteineresiduesintheiractivesiteforgoldorDNAfor
copper NHC complexes.
Metal Carbonyl Complexes
Metal CO complexes (or metal carbonyls) are organome-
tallic complexes containing one or more carbon monoxide
ligands.Sofar,alargevarietyofdifferentmetalcarbonylcom-
plexes with promising antiproliferative properties have been
reported including the above-mentioned rhenium and os-
miumderivativesbutalsovariouscobalt,
208iron,
40chromium
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(half-sandwich),
209,210 ruthenium,
211 or manganese
212,213
bioorganometallic species.
For example, an increasing number of reports deal with the
biologicalpropertiesofalkynehexacarbonyldicobalt(Co2(CO)6)
species,
208 a class of bioorganometallic complexes whose
cytotoxic properties had been mentioned first in 1987
214 and
then studied inmoredetailagain since1997.
215 During subse-
quent structure-activity studies, a complex containing an
acetylsalicylic acid (aspirin) derived ligand emerged as a lead
compound for this class of drugs (57 in Figure 21).
216,217 The
importanceoftheaspirinpartialstructureforthebiochemical
properties of this compound is also reflected in its name
Co-ASS, which includes the German abbreviation for aspirin,
ASS. Clinical studies on aspirin and other nonsteroidal anti-
inflammatory drugs (NSAIDs) have indicated a correlation
between the long-term intake of NSAIDs and positive effects
forcancerpatients(mainlyconcerningasubstantialdecreasein
recidive risks), thereby making NSAIDs interesting candidates
for chemoprevention and combination chemotherapy.
218 On
the basis of these observations, the NSAID-like character of
Co-ASS and related complexes was studied in more detail and
appeared to contribute significantly to the activity of this lead
compound.
217 Co-ASS strongly inhibits the NSAID main
target enzymes COX-1 and COX-2,
217 a n do nt h eb a s i so fi t s
good stability,
219 it could be concluded that the active species
was indeed the intact organometallic complex. Recently, it was
confirmed that Co-ASS exhibited several biochemical proper-
ties related to the reported antitumoral effects of NSAIDs
including induction of apoptosis, inhibition of PGE2 forma-
tion,andtriggeringofantiangiogeniceffects.
220Interestingly,it
could be shown that Co-ASS acetylated several lysine residues
of its putative main target COX-2, in contrast to aspirin, which
acetylates a serine residue in the active site of the enzyme.
220
In this context, it should be noted that a COX-2 related
mechanism, as seen with Co-ASS, most probably does not
exist for other hexacarbonyldicobalt species not containing
NSAID derived ligands. A variety of hexacarbonyldicobalt
species with interesting biological properties have been re-
ported including nucleosides (e.g., 58),
221 carbohydrates,
222
peptide derivatives (e.g., 59),
223 and complexes with hormon-
ally active ligands (Figure 21).
224-226 On the basis of the
chemical structures of these compounds, it is very likely that
different biological structures are targeted, and one might
speculate that the Co2(CO)6 moiety modifies the interaction
with those biomolecules. Thus, for complexes with hormone
derived ligands, it was demonstrated that the hormonal
activity and the receptor binding were retained. For nucleo-
side ligand-containing derivatives, preliminary studies indi-
cated that the uptake of the compounds into the tumor cells
mightcorrelatewiththeircytotoxicactivity.Becauseasimilar
dependencewasalsoobservedfortheuptakeintothenuclei,it
canbeconcludedthatforthenucleosidederivatives,apossible
modeof actionmight involveaninteractionwiththeDNAor
the DNA related enzyme machinery.
221
Hormonal activity has also been described for metal CO
complexes other than hexacarbonyldicobalt alkynes, mainly
by the group of Jaouen.
227,228 Thus, several metal carbonyl
derivatives of estradiol or hydroxytamoxifen exhibited good
estradiol receptor binding affinity, and for some derivatives
antiproliferativeactivitywasalsoobserved.Forexample,hydro-
xytamoxifene derivatives containing a cyclopentadienylmetal
tricarbonyl moiety (see 60) were well recognized by both ERR
and ERβ and triggered antiproliferative effects (see also the
section Metallocenes and Rhenium Organometallics above).
227
In the case of iron-containing metal carbonyl complexes,
nucleoside containing derivatives have been the subject of
major attention. Thus, the iron CO complex N69 (61 in
Figure 21) significantly induced apoptosis in tumor cells
but did not trigger unspecific necrotic effects (see also com-
pound 2 in Figure 3).
40 These properties are highly rele-
vant for further development of these compounds into sui-
tabledrugcandidates.Additionally,furtherunspecificeffects
of the iron diene unit of 61 could be ruled out, as close
analogues of the lead compound and the (non-iron-contain-
ing) free ligand were notactive.
40 Interestingly, theapoptosis
induction in melanoma cells by 61 was independent of
caspase activation but could be related to ROS formation.
It was suggested that the N69-mediated ROS production
could be due to its capacity as an iron donor with the
nucleoside ligand functioning as a carrier.
229
In the above-mentioned examples, the structural influence
of the CO ligands on the bioactivity and molecular receptor
interaction is not yet clear but increasing evidence exists
that the presence of these ligands is crucial for the efficacy
ofthe compounds. In this context,itis important to note that
the position of a CO ligand in the active site of the target
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enzyme Pim-1 could be confirmed by X-ray crystallography
for a staurosporine-derived ruthenium kinase inhibitor (see
Figures17and18formoredetailsonthisclassofcomplexes).
From this crystal structure it is obvious that the CO ligand
(together with a cyclopentadienyl ring) occupies a binding
pocket in the active site of the enzyme, which is usually filled
by the carbohydrate moiety of staurosporin.
175 On the basis
of these data, it can be speculated that similar biomolecular
target interactions might also be relevant for other metal CO
complexes.
Besidestheirpotentialroleinthemolecularinteractionwith
biologicaltargets,anotherrelevantfeatureofCOcomplexesis
their high lipophilicity, which led to increased cellular uptake
levelsina number of studies.
217,221,222 Itcan thusbe addition-
ally speculated that stable CO ligands trigger an enhanced
bioactivity because the cellular uptake of the (bioactive)
ligand of the complex is increased.
Anotherinterestingconceptforthebiomedicaluseofmetal
carbonylspeciesisthefactthattheCOligandscanbereleased
under appropriate conditions, enabling the released carbon
monoxide to trigger pharmacological effects.
230 Thus, CO
releasing properties have also been recently reported for
hexacarbonyldicobalt complexes
231 and for manganese car-
bonyl derivatives, where photoinduced cytotoxic effects were
observed (see 62).
212 These properties are elegantly used in a
broader context by the design of carbon monoxide releasing
molecules (CORMs), which might find future application in
medicine because of their powerful vasodilatory, anti-inflam-
matory, and antiapoptotic properties. For a more detailed
description of the group of CORMs the reader is referred to
recent reviews on this topic.
232,233
Metal carbonyl species have also shown potential for
application as diagnostics. While this topic is also beyond
the scope of this Perspective, the concept shall be mentioned
briefly here: The fact that intensive IR vibrations of the CO
ligandsaresuitablefordetectionpurposesfounduseintheso-
called carbonylmetallo immunoassay (CMIA).
234 For exam-
ple,itwaspossibletodevelopassaysforthesensitivedetection
of hormones or antiepileptics and to obtain metal-carbonyl-
dendrimer-antibody bioconjugates with a broad range of
applications.
235
Miscellaneous
Other strategies and ideas for the treatment of cancer
involving the use of organometallics were recently employed
byTherrien et al. They investigated the possibilityof combin-
ing the chemotherapeutic activity of organometallics with
photosensitizing agents for photodynamic therapy (PDT).
Withthisinmind,theypreparedaseriesofRu(II) (63),Os(II)
(64), Rh(III) (65), and Ir(III) (66) complexes containing
porphyrinderivatives,whichareknown tobe efficientphoto-
sensitizing agents (Figure 22).
236 The photoactivation pro-
duces singlet oxygen and radical species, which results in
tumor cell death. All complexes had similar moderate cyto-
toxicity toward cancer cells with the exception of the Rh
complex, which was found to be nontoxic. Importantly, the
Ru(II) complexes exhibit excellent phototoxicity toward mel-
anoma cells when exposed to laser light at 652 nm.
236 The
exact mechanism of action of these Ru complexes is not yet
determined,butithasbeenshownbyfluorescencemicroscopy
that they were not accumulating in the nucleus, suggesting a
non-DNA mode of action. In a similar perspective, very
recently, the same group described the use of sawhorse-type
diruthenium tetracarbonyl complexes containing porphyrin-
derived ligands as highly selective photosensitizers for female
reproductive cancer cells.
237
Itwasalsoshownbythesamegroupthatthebridgingoftwo
Ruorganometallicsthroughaferrocenemoiety(65,Figure23)
increased considerably the cytotoxicity of the compounds
compared to the monoruthenium analogue.
238 A difference
inredoxpotentialoftheferroceneunitshasbeenproposedasa
possiblecauseoftheincreasedcytotoxicity.Remarkably,these
compoundswereequallypotentagainstcisplatin-resistantand
-nonresistant cell lines, which is indicative of a mode of action
different from that of cisplatin.
238 The concept of multinu-
clearity for the improvement of anticancer activity has also
been demonstrated by Hartinger et al.
239-241
Another original example of the use of organometallics for
cancer therapy was to employ an “organometallic cage” to
transport metal complexes, namely, [Pd(acac)2] and[Pt(acac)2]
Figure 22. Examples of Ru(II), Os(II), Rh(III), and Ir(III) organometallic porphyrin compounds.
Figure 23. Diarene ruthenium compound bridged by a ferro-
cene.
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(acac=acetylacetonato) into cancer cells “by encapsulation”.
The trigonal-prismatic “cage” molecule consists of six half-
sandwich (η
6-arene)Ru (68,F i g u r e2 4 )o r( η
5-pentamethyl-
cyclopentadienyl)Rh units held together by two trigonally
substituted triazine and additional chloro or oxaloto bridges.
Interestingly, once inside the cells, [Pd(acac)2] or [Pt(acac)2]i s
released and exerts a cytotoxic effect.
242 It was shown that
thesecageswereextremelystable,evenathightemperatures.It
was further demonstrated that the empty cage and the Pd and
Ptcomplexesbythemselveswerelesstoxicthantheir“complex
in a complex”.
242 The exact mechanism of action for these
compounds is still unknown, but it is postulated that the
organometallic cage facilitates the cellular uptake. The use of
such metallaboxes is currently being investigated by this
group.
243
Sadler,Brabec,andco-workersalsoinvestigatedthephoto-
activation of dinuclear ruthenium(II) arene complexes to
trigger DNA binding and fluorescence.
244 They showed that
upon irradiation with UV-A light, some of their complexes
underwent arene loss. Interestingly, the fluorescence of the
unbound arene is roughly 40 times greater than when it is
complexed to the Ru center, therefore enabling visualization
of the intracellular localization of the arene moiety. Further-
more,irradiationalsohadasignificanteffectonDNAbinding
in that the formed ruthenium adducts strongly block RNA
polymerase. These complexes therefore have the potential to
combinephotoinducedcelldeathandfluorescenceimagingof
the location and efficiency of the photoactivation process.
Conclusion and Perspective
In this Perspective, we summarized recent developments
toward the use of organometallic compounds as anticancer
drugcandidates.Thegeneralnotionthatorganometalliccom-
pounds would be sensitive to air and water and therefore
unstable under physiological conditions and unsuitable for
medicinal purposes has been disproved. Rather, our above
analysis demonstrates a broad range of classes of compounds
that are stable and well characterized for biological applications.
Organometallic compounds are frequently kinetically inert
and amenable to(multiple) derivatization reactions. They are
thus suitable for conventional structure-based drug design,
including computer docking experiments similar to those for
the more traditional organic drug candidates. The successful
development of ruthenium kinase inhibitors by Meggers and
co-workers impressively demonstrates this capacity. A recent
multistep synthesis of chromium-based antibiotics modeled
after the natural lead structure platensimycin further demon-
strates that even complicated lead structures can be realized
with organometallic cores.
210 With the overcoming of the
long neglect of these so-called bioorganometallics by both
industrial and academic drug research, an increasing number
of emerging drug classes impressively demonstrates that the
fieldoffersabroadvarietyofunexploredoptionsforsynthetic
medicinal chemistry.
By combination of modern organometallic synthesis with
state-of-the-art biochemical studies, the field has advanced
markedly from the rather crude “synthesis-and-cytotoxicity-
screening” approach that was common just a few years ago.
Organometallic chemists frequently collaborate with medic-
inal chemists, biochemists, and molecular or cell biologists.
Arrivingattheforefrontofmedicinalchemistryresearch,they
employ the whole toolbox of modern biomedical research,
including structural biology, computer-aided design, and
biochemical and cell-based assays to gain a deep insight into
possible cellular targets and the molecular details of target
interactions.Foranumberofcompounds,eveninvivotesting
is in progress. We have pointed to prior work and mentioned
in vivo results in the respective sections. More studies are
currently underway but not yet publicly available. However,
we would certainly expect that this is the next frontier for
medicinalorganometallicchemistry,onthewaytobringingat
least some of the most promising organometallic drug candi-
dates described herein as drugs to the market.
In this Perspective, we have tried to emphasize such bio-
chemical studies (where available) to elucidate molecular
t a r g e t sa n dm o d e so fa c t i o n .W h i l ei ti sc l e a rt h a tf o rm a n y
organometallic complexes interesting bioactivities were ob-
served,themolecularmodesoftargetinteractionorthetargets
themselves are not perfectly clear for each class of compounds
atthisstage.Itisclear,however, thatDNAisnotthetargetfor
most bioorganometallics and protein interactions (e.g. with
cyclooxygenases, kinases, thioredoxin reductase or hormonal
receptors) are major modes of action. Moreover, some metal
complexes may even exhibit completely novel, metal-specific
modes of action, such as the ferrocifen derivatives in which the
metallocene acts as a redox antenna for intramolecular redox
activtion. Clearly, exploitation of the distinct properties of
metal complexes for biologically active compounds deserves
more attention. It is hoped that the advent of organometallic
complexes in clinical trials will improve acceptance of such
compoundsinthepharmaceuticalindustryandsupportfurther
research into the fascinating field of organometallic drugs and
their biological targets.
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